Form 4: Cytokinetics EVP Buys and Sells Stock

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, reported transactions involving the acquisition and sale of common stock and stock options.

Summary

• Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., engaged in stock transactions on April 7, 2026.
• Malik acquired 3,500 shares of common stock at $7.80 per share and sold 3,500 shares at $65.21 per share.
• Additionally, Malik acquired 1,000 shares of common stock at $10.60 per share and sold 1,000 shares at $64.75 per share.
• Following these transactions, Malik beneficially owns 153,902 shares of common stock directly.
• The filing also details transactions related to non-qualified stock options, including the acquisition of 3,500 options at an exercise price of $7.80 and 1,000 options at $10.60.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports routine insider transactions under a 10b5-1 plan, which are common and do not inherently signal positive or negative company performance.

Positives

• The EVP acquired additional shares and stock options, indicating potential confidence in the company's future.
• The sale of shares at a significantly higher price than the acquisition price for some transactions suggests profitable trades.
• The EVP continues to hold a substantial number of shares (153,902) directly, indicating continued significant beneficial ownership.

Negatives

• The EVP sold a significant number of shares (3,500 + 1,000 = 4,500) at a much higher price than they were acquired, realizing substantial gains which could be interpreted as taking profits.
• The acquisition prices for some stock options ($7.80 and $10.60) are considerably lower than the sale prices of common stock ($65.21 and $64.75), highlighting a large spread between acquisition cost and market value at the time of sale.

Risks

• The filing does not explicitly mention any risks or challenges.
• The transactions are part of a pre-arranged trading plan under Rule 10b5-1(c), which is designed to mitigate insider trading concerns but does not eliminate the inherent risks associated with stock price fluctuations.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions are reported as executed on a specific date.

Management Comments

• The filing is a statement of changes in beneficial ownership and does not contain direct quotes or paraphrased statements from management regarding strategy or performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported activity by an EVP of Research & Development at Cytokinetics Inc. is typical for executives managing their personal investment portfolios, especially when utilizing 10b5-1 plans.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions may be viewed neutrally as part of a pre-arranged trading plan. Significant sales by executives can sometimes be perceived negatively, but the context of a 10b5-1 plan mitigates this concern.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The filing itself represents a completed action (reporting transactions) and does not outline future steps for the company or the reporting person beyond standard compliance.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Common Stock, Cytokinetics Inc., CYTK, Beneficial Ownership, Stock Transactions, Executive Compensation